Article Information
History
- June 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Hiroshi Mukae1,
- Hiroshi Yotsuyanagi2,
- Norio Ohmagari3,
- Yohei Doi4,5,
- Hiroki Sakaguchi6,
- Takuhiro Sonoyama6,
- Genki Ichihashi6,
- Takao Sanaki7,
- Keiko Baba7,
- Yuko Tsuge6 and
- Takeki Uehara6,*
- 1Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- 2The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 3Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
- 4Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- 5Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
- 6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- 7Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
- ↵*Corresponding author: Takeki Uehara, Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan Email: takeki.uehara{at}shionogi.co.jp, Telephone: +81-6-6209-6907
Posted June 26, 2022.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
